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Abstract
Pediatric patients with ulcerative colitis (UC) represent a high-risk population with severe
disease that requires hospitalization. This study evaluates the impact of implementing an acute
UC management protocol on 39 pediatric patients. After analysis, significant trends were shown
for admitted pediatric patients post-protocol implementation, helping to coordinate multidisciplinary care sooner during a hospital stay. The patients were more likely to have a surgical
consult, and the surgical consult was completed closer upon admission. The median length of
hospital stay did not change, total parenteral nutrition use was increased, and oral steroids upon
discharge were decreased. Anti-tumor necrosis factor alpha was given to more patients earlier
upon admission, and the colectomy rate did not change but was more likely to be conducted
sooner as an inpatient procedure. While further research with a larger patient population is
needed, the benefits of an acute UC management protocol have been shown.
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Introduction
Inflammatory bowel disease (IBD) is a term used to describe disorders that involve
chronic inflammation of the digestive tract. The two main forms of IBD include Crohn’s disease
and ulcerative colitis (UC). Although these two diseases share some characteristics, they can be
differentiated by specific clinical, endoscopic, and specialized histological features (Ordás,
Eckmann, Talamini, Baumgart & Sandborn, 2012). UC is confined to the colon, and
inflammation is generally limited to the mucosal surface. Crohn’s disease can cause
inflammation in any part of the gastrointestinal (GI) tract and penetrate the deeper layers of the
tissue (Baumgart & Sandborn, 2012).
Currently, there is no cure for IBD. Treatment is centered around management of
symptoms and prevention of complications, with the goal of remission. Targets for remission
include resolution of clinical symptoms, defined as recovery of rectal bleeding with positive
changes in bowel habits, and endoscopic healing (Ungaro, Mehandru, Allen, Peyrin-Biroulet &
Colombel, 2019). Patients with UC may reach and maintain remission with oral medications
(Higgins, 2010). Sulfasalazine and aminosalicylates (mesalamine, olsalazine, and balsalazide),
are usually first-line treatment with an expected remission rate of about 50% (Danese & Fiocchi,
2011). Although aminosalicylates are the main choice of treatment for mild to moderate UC
(Nielson & Munck, 2007), approximately 15% of patients with UC will have subsequent relapses
or flares that can turn into a severe exacerbation (Doherty & Cheifetz, 2009). Corticosteroids,
such as oral prednisone are the first-line treatment used to treat flares (Carter et al., 2004).
Intravenous (IV) steroids, immunosuppressants and biological drugs such as monoclonal
antibodies or tumor necrosis factor (TNF) inhibitors are often used in moderate to severe
exacerbation of the disease (Lis, Kuzawińska & Bałkowiec-Iskra, 2014).
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Severe exacerbation of UC symptoms or acute UC may constitute a medical emergency
requiring hospitalization. Patients hospitalized for acute UC benefit from a multidisciplinary
team comprising of a gastroenterologist and a colorectal surgeon (Kedia, Ahuja & Tandon,
2014).
Since pediatric patients hospitalized with acute UC require a rapid multidisciplinary
approach including coordination of medical, surgical, and nutritional interventions, an acute UC
management protocol was created. A protocol is a standard set of rules or procedures to be
conducted and followed in formal situations, which allow many individuals to communicate
efficiently with each other. The goal of our acute UC management protocol was to standardize
and improve care, ensuring that all rotating caregivers at an academic medical center follow the
same implemented clinical management protocol for any patient hospitalized for UC
exacerbation. This protocol was created by pediatric gastroenterologists and surgeons with
expertise in IBD and initiated in November 2014. To assess the efficacy of the protocol, medical,
surgical, and nutritional interventions in hospitalized pediatric patients were measured before and
after implementation of the management protocol.
The development of the project flowchart system (Appendix A), clearly defines steps and
processes to apply to the care of a patient admitted with a UC flare. This protocol begins with all
acute UC patients being admitted to the GI floor of the hospital. The protocol requires the
gastroenterologist to document the Pediatric Ulcerative Colitis Activity Index (PUCAI) score on
a daily basis. The PUCAI is a validated and frequently used primary outcome measure to reflect
disease activity in pediatric UC (Turner et al., 2009). The protocol includes an initial assessment
with surgeons upon admission, to involve surgeons early on in case medical management fails,
and to introduce the possibility of a colectomy to the family to improve their knowledge and
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understanding of surgical intervention should it need to happen during the admission. A
colectomy is a surgical procedure to remove all or part of the colon. A colectomy may be
considered on any day in the management of acute UC patients if medical management does not
produce the desired outcomes and may be required emergently if patient develops intestinal
perforation, exsanguinating hemorrhage or toxic megacolon (Macken & Blaker, 2015). If by
hospital Day 5 a patient’s PUCAI score is greater than 65, this predicts a need for greater
escalation of therapy or surgery. Patients who fail treatment or who do not respond to therapy
within 72 hours will require a colectomy per the acute UC protocol. The involvement of
surgeons at the time of admission is critical. In children, 10% of acute UC patients undergo a
colectomy prior to discharge, with a cumulative colectomy rate at 1 year of 20% (Rosen, 2015).
Although most patients will respond to medical therapies, a colectomy can be lifesaving for
some patients (Maken & Blaker, 2015).
The acute UC management protocol also requires a nutrition evaluation at the time of
admission. The Nutrition Evaluation (Appendix B) begins with access to STRONGkids to
determine individual caloric needs. STRONGkids is a nutritional screening tool for hospitalized
children, established to predict a negative weight for height standard deviation score in a lengthy
hospital stay (Huysentruyt et al., 2013). Hypoalbuminemia in UC is predominately due to protein
loss from severe colitis, not from malnutrition (Hendrickson, 2002). If albumin levels are below
2.0 g/dL, the physician should consider IV albumin supplementation and begin total parenteral
nutrition (TPN), even if enteral nutrition is preferred. It is often preferred over parenteral
nutrition, since it is associated with significantly fewer complications than parenteral nutrition in
acute colitis (Seres, Valcarcel & Guillaume, 2013). Nutrition consultations are important to
establish acute and chronic nutritional needs, to identify if a patient is not meeting oral caloric
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needs, and to assist the physician in a decision about whether tube feedings and/or parenteral
nutrition is needed. This will also allow for planning for the placement of a peripherally inserted
central catheter (PICC). Since these patients are prone to malnutrition and its detrimental effects
(Burke, Lichtenstein, & Rombeau, 1997), it is important to address any nutritional issues early
on during admission so that the patient has the best chance of recovering during and after
hospitalization for acute UC.
At admission, the protocol advises initial medical management with IV steroids for 48
hours as well as appropriate nutritional support. The response to steroids is indicated by
improvement in patients’ symptoms (decreased stool frequency, urgency and rectal bleeding,
improved stool consistency, minimized abdominal pain, and improvement in general wellbeing
utilizing the PUCAI score) and improved lab parameters. Due to potential side effects, there is a
need to limit the overall duration of corticosteroid use for flares, and physicians need to institute
a corticosteroid-sparing agent whenever possible for long-term disease maintenance (Feuerstein
et al., 2019). After 3 days, a PUCAI score greater than 45 predicts likely failure to the first line
of treatment, steroids. Anti-TNF therapy can be used in acute steroid-resistant UC patients who
prefer to avoid surgical management if possible (Gibson et al., 2015). If family opts for antiTNF, the protocol advises starting infliximab at 10 mg/kg. This dose is commonly used in to
treat pediatric UC (Nattiv et al., 2012). Acute UC patients benefit from this dose for induction
into remission (Turner et al., 2012).
The objective of this study was to evaluate and measure the involvement of physicians,
surgeons, and registered dietician services during a pediatric acute UC admission before and
after protocol implementation. Data regarding patients acute UC hospitalization was collected,
and data was extracted to assess clinical outcomes.
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We hypothesized that the implementation of a standardized pediatric acute UC protocol
would show significant effect on the timing of nutrition and surgical evaluation when a patient is
admitted to the GI service for acute UC flare. We were also interested in evaluating the effect of
the acute UC protocol on overall length of admission, the timing and frequency of colectomy,
and the timing and outcomes of medical intervention implemented, per protocol, in a
standardized fashion (anti-TNFα, TPN, steroids). Preliminary study findings were previously
published as an American Gastroenterological Association (AGA) abstract (Milewski et al.,
2016).
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Methods
This study was reviewed by both the University Human Subjects Review Committee
(UHSRC) at Eastern Michigan University (2018), and the Medical School Institutional Review
Board (IRBMED) of the University of Michigan Medical School (2015; see Appendices C and
D). Both IRBs ruled that this was not considered human subject research and did not require IRB
approval since it does not satisfy the definition for human subject research under federal
regulation 45 of the Code of Federal Regulations (CFR) section 46.102.
Data was collected using retrospective chart review of the electronic medical record and
stored with a numeric identifier to remove protected health information (PHI). After IRB review
for this study, data for every pediatric patient hospitalized for acute UC exacerbation and as an
acute UC flare was then captured in chronological order from January 2013 up to the protocol
implementation date on November 1, 2014. In addition, the succeeding patients admitted with
acute UC characteristics after the management protocol implementation date were identified by
physicians during weekly meetings until January 2016 and collected into the same database.
The following data was extracted from each hospitalization record: admission
date/discharge date, nutrition consult ordered/completed, surgery consult ordered/completed,
initiation of TPN, whether patient had a colectomy and when, and if the patient was discharged
on oral steroids. This would allow a review to see if there was a difference in outcomes before
and after management protocol implementation.
Analysis
Data collected for the study was retrieved from the electronic medical record (EMR) and
placed into a password protected Excel worksheet. Data from pre-protocol and post-protocol
implementation were grouped for analysis. Statistical descriptive analyses were conducted by

7

using Pearson’s chi-square, and Fisher’s exact test to evaluate the data and investigate
differences between the groups. The p-value used for all tests of significance was p = .05.
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Results
There were a total of 39 patients admitted for acute UC exacerbation included in this
study (Table 1). Table 1 shows patient demographics. Twenty of these patients were reviewed
pre-protocol (from January 2013 to November 2014), and 19 patients collected post-protocol
implementation (November 2014 to January 2016).
Table 1.
Acute UC Protocol Management —Patient Demographics
Description
Frequency
All Patients
Age

Gender
Diagnosed prior to admission
Exposure to anti-TNF before admission
On oral steroids prior to admission

0-9
10-15
16-20
Male
Female
Yes
No
Yes
No
Yes
No

6
22
11
21
18
38
1
10
29
11
28

Frequency
Before
Protocol
4
9
7
12
8
19
1
2
18
7
13

Frequency
After
Protocol
2
13
4
9
10
19
0
8
11
4
15

The length of admission was recorded for all acute UC patients for both before and after
implementation of the acute UC management protocol is shown in Figure 1. Before protocol
implementation, there were a total of 20 acute UC hospitalizations that ranged from 3 to 18 days
in length (mean 7.4 days), with 6.5 days as the median length of stay. After protocol
implementation, there were 19 consecutive hospitalizations that ranged from 3-53 days in length
(mean 15.9 days; p = .02), with a median of 6 days, represented by a dashed line (p = .73).
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Figure 1. Length of hospitalization.

Whether or not a registered dietician’s nutrition evaluation was completed, along with the
average day of hospitalization that the consult was completed, is shown in Figure 2. The
frequency of nutrition consults being completed before and after protocol implementation were
both 95% (p = 1). There was no significant difference on the average day the nutrition consult
was completed during hospital stay (3.1 vs. 2.5 days, p = .25).

Figure 2. Nutrition evaluation and consultations.

Three medical interventions were recorded during the acute UC admission as shown in
Figure 3. The first intervention studied was whether or not the patient received an anti-TNF
alpha inhibitor therapy medication. Before the protocol was implemented, only 20% of patients
received this medication (on average hospital Day 9), and after the protocol, 58% of patients
received anti-TNF during admission (p = .02) (on average hospital day 4.3; p = .02).
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TPN was the second medical intervention studied. Prior to the protocol implementation,
only 5% of patients studied received intravenous nutrition, whereas 53% of patients received
TPN after protocol implementation (p = .001). The third medical intervention shown in Figure 3
is whether or not acute UC patient were discharged on oral steroids. Prior to the protocol, 90% of
patients were discharged on oral steroids, and after the protocol, only 53% were discharged on
oral steroids (p = .01).

*= p ≤ .05

Figure 3. Medical interventions.

Figure 4 shows the percentage of surgical consultations completed, along with the
average day the surgical consult was completed. Before protocol implementation only 15% of
patients had a surgical consult ordered, but after protocol implementation, 79% of patients had a
surgical consult ordered (p = .0002). The average hospital day that the surgical consultation was
completed prior to protocol implementation was on Day 10.7. After protocol implementation, the
surgical consult was completed 7.1 days sooner, on average Day 3.6 (p = .04).
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*= p ≤ .05

Figure 4. Surgical consultation completed.

Figure 5 shows a total of 16 of the 39 (41%) acute UC patients underwent an inpatient or
scheduled outpatient colectomy following hospitalization(s) for acute UC flare(s), 7 out of 20
(35%) patients before management protocol implementation (indicated by a dashed line), and 9
out of 19 (47%) patients received colectomies after protocol implementation. The two patients
who had an initial admission before the protocol implementation but were discharged after are
included in the after group, since they had subsequent readmissions after protocol
implementation. The average day patients underwent colectomy was significantly sooner (p =
.02) after protocol implementation (mean = 64.1 days) than those with initial admission for flare
prior to the protocol (mean = 225.9 days).
Figure 5 also shows 14% (1 patient) of the colectomy patients underwent the surgery
during their admission (inpatient colectomy) before the management protocol was introduced,
indicated by red square in Figure 5. After implementation of the protocol, 66% (6 patients)
received the surgery as inpatients (p = .04).
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Figure 5. Timing from initial acute UC admission to colectomy.

Table 2 summarizes the location of the patients who underwent a colectomy. Either
during initial hospitalization for flare, during a hospitalization following a re-admission for flare,
or as a scheduled surgical procedure after discharge- due to failure of outpatient medical
management after previous hospitalization(s) for flare(s).
Table 2.
Patients Colectomy Service: Summary of location/service when
colectomy was performed
Total Colectomies
Description
Before
After
Protocol
Protocol
Inpatient–initial hospitalization
1
4
Inpatient–re-admission
0
2
Outpatient–scheduled procedure
6
3
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Discussion
The purpose of this study was to evaluate the implementation of an acute UC
management protocol and identify the effect on the frequency and timing of the evaluation by
surgeons and dieticians, the duration of hospitalization stay, the frequency of medical
intervention use (anti-TNFα, TPN, steroids), and the occurrence of colectomy due to treatment
failure. The results were obtained from pediatric patients being admitted at an academic medical
center for acute UC (n = 39) from January 2013 to January 2016. They were collected both
before (n = 20) and after (n = 19) acute UC management protocol implementation on November
1, 2014.
The review of length of stay revealed there was a significant increase in the mean length
of hospitalization (7.4 vs. 15.9 days, p = .02). This was possibly prolonged secondary to postoperative complications. The median length of hospitalization was not significantly different (6
vs. 6.5 days, p = .7).
Regarding the involvement of nutritional intervention, the nutrition evaluation completed
by a registered dietician was completed with the same rate of frequency (95% vs 95%, p = 1).
Nutrition consults were completed on average 0.6 days sooner after protocol implementation, but
this was not significantly different (3.1 vs. 2.5 days, p = .25).
In regard to medical interventions, after protocol implementation, more patients were
given anti-TNF alpha inhibitor therapy (20% vs 58%, p = .02) and given on average 4.7 days
sooner (9 vs. 4.3 days; p = .02) after the management protocol was instituted. After protocol
initiation, significantly more patients received TPN (5% vs. 53%, p = .001) during their hospital
stay, and lastly, significantly fewer patients were discharged on oral steroids (90% vs. 53%, p =
.01). We hypothesize that patients subjected to the acute UC management protocol were assessed
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more closely and objectively for response to steroids and that they were thus less likely to be
discharged on unnecessary steroids, possibly sparing them negative side effects of this drug
category. Perhaps just implementing a management protocol influences care-providers, actions
by prescribing more TNP and more anti TNFα, which could lead to less patients being
discharged on oral steroids.
The involvement of surgeons completing a surgical consult increased significantly after
protocol implementation (15% vs. 79%, p = .0002). These surgical evaluations were also
completed sooner (Day 10.7 vs. Day 3.6, p = .04) during hospitalization. Although there
appeared to be an improvement on the surgical consult being completed sooner, the t-test showed
it was not statistically significant (p = .18), possibly due to the fact that surgical consult was only
ordered for three patients prior to the protocol and for 13 patients after the protocol.
The majority of acute UC patients did not undergo a colectomy (n = 23; 59%). The
protocol implementation did not significantly increase the rate of undergoing colectomy during
stay, possibly due to small sample size (n = 16), with a relatively small number of
hospitalizations after the protocol that were possibly prolonged secondary to post-operative
complications. The total number of patients undergoing a colectomy during admission (n = 7)
decreased after protocol implementation, although there was not a significant difference (p =
.06). This trend demonstrates that if a patient will ultimately need a colectomy, they are being
done more often in-patient after protocol implementation. The earlier and more frequent surgical
consults may have led to more inpatient colectomies, which could of ultimately lead to less
discharge on steroids. Since this analysis was done with a such small sample size, a p-value of >
0.05 only signifies that the evidence is not adequate to reject the null hypothesis. This does not
imply that the two treatments are equivalent.
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Inconsistency in care sometimes encountered at an academic hospital for complex, sick
patients such as those admitted with acute UC symptoms is problematic. First, families may hear
conflicting information from various caregivers, leading to confusion and a lack of trust in the
medical system. Second, it is impossible to tell whether a care pathway provides the best
outcomes for a patient if it is not being used consistently and appropriately. Third, necessary care
may be delayed if a multidisciplinary approach is not taken early on during a hospital stay.
Implementation and evaluation of an acute UC management protocol allowed us to identify and
understand these problems through data measures. Continuing to educate rotating staff is
essential to supporting ongoing, correct use of the protocol to continue to study outcomes. We
would benefit from ongoing use of this protocol with data collection so that clinical outcomes
can be more closely studied on a larger population basis.
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Conclusions
An evaluation of the effect of implementing an acute UC management protocol was
completed on 39 pediatric acute UC hospitalizations. After analysis, significant trends where
shown for admitted pediatric patients post management protocol implementation helping to
coordinate multi-disciplinary care sooner during a hospital stay. Although the median length of
hospital stay did not change, anti-TNFα was given earlier and to more patients. The patients were
more likely to have a surgical consult, and the surgical consult was closer to admission. More
patients received TPN, and fewer patients were discharged on oral steroids. The patients’
nutritional consults during hospitalization continued to be early upon admission for both pre- and
post-protocol implementation. The overall colectomy rate did not change but was more likely to
be conducted sooner and as an inpatient procedure. Additional research is warranted, but with the
statistically significant outcomes gathered from this small study, the meaning for practice going
forward will hopefully spare patients of negative side effects of steroids and continue to involve
all rotating caregivers in the patients plan of care. While further research with a larger patient
population is needed, the benefits of an acute UC management protocol have been shown.
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Appendix C: Response Letter from EMU Human Subject Review Committee
Jan 12, 2018 2:41 PM EST
Samantha Milewski
Eastern Michigan University, School of Health Sciences
Re: Initial - UHSRC-FY17-18-222 Evaluation of Pediatric Acute Ulcerative Colitis Protocol
Dear Dr. Samantha Milewski:
The Eastern Michigan University Human Subjects Review Committee has rendered the decision
below for Evaluation of Pediatric Acute Ulcerative Colitis Protocol.
Decision: No Human Subjects Research
Findings: Your project does not require UHSRC review in accordance with federal regulation 45
CFR 46.102 because it does not meet the Federal definition of human subject research.
UHSRC policy states that you, as the Principal Investigator, are responsible for protecting
the rights and welfare of your research subjects and conducting your study as described in
your protocol.
Please contact human.subjects@emich.edu with any questions or concerns.
Sincerely,
Eastern Michigan University Human Subjects Review Committee
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Appendix D: Response Letter from UofM Human Subject Review Committee
Medical School Institutional Review Board (IRBMED)
2800 Plymouth Road, Building 520, Suite 3214, Ann Arbor, MI 48109-2800
phone (734) 763 4768 • fax (734) 763 9603 • irbmed@umich.edu
Subject: Notice of Determination of “Not Regulated” Status for [ HUM00105220]
SUBMISSION INFORMATION: Title: Evaluation of pediatric acute ulcerative colitis protocol
Full Study Title (if applicable): Evaluation of an inpatient protocol for management of
acute ulcerative colitis exacerbation in pediatric patients Study
eResearch ID: HUM00105220
Date of this Notification from IRB: 10/9/2015
Date of IRB Not Regulated Determination: 10/9/2015
IRB NOT REGULATED STATUS:
The IRBMED has reviewed the application referenced above and determined that, as currently
described, it does not require IRB approval because it does not satisfy the definition
research under 45 CFR 46.102(d), 21 CFR 56.102(c), or U-M policy as described in
Human Research Protection Program Operations Manual Part 4. Research is defined as
“…a systematic investigation, including research development, testing and evaluation,
designed to develop or contribute to generalizable knowledge.”
The purpose of this Quality Assurance/Quality Improvement (QA/QI) initiative is limited to
Improving healthcare quality and/or delivery; and/or Collecting, measuring, and/or reporting
patient or provider data for clinical, practical, training or administrative purposes
In accordance with OHRP FAQ on this subject (see http://www.hhs.gov/ohrp/policy/faq/qualityimprovement-activities/improve-quality-of-patient-care.html and
http://www.hhs.gov/ohrp/policy/faq/quality-improvement-activities/measuring-reportingprovider-performance-data.html) there is no requirement for such activities to undergo review by
an IRB, or for these activities to be conducted with provider or patient informed consent.
NOTE: QA/QI initiatives sometimes also constitute non-exempt human subjects research under
the HHS regulations: these require IRB review and approval. See OHRP FAQ at
http://www.hhs.gov/ohrp/policy/faq/quality-improvement-activities/types-of-qualityimprovement-efforts.html and http://www.hhs.gov/ohrp/policy/faq/quality-improvementactivities/need-to-be-reviewed.html
Any proposed changes that may introduce a research component, or may exceed the approval
conditions of any other non-IRB reviewing committees, must be submitted as an
amendment through eResearch.
DATA SECURITY GUIDELINES AND CONFIDENTIALITY PROTECTIONS:
You are responsible for maintaining data for the QA/QI initiative in a secure manner with the
appropriate level of anonymity, confidentiality, or de-identification as a key factor in
ensuring a low risk threshold for the participants and the University. The IRB recommends
you follow the U-M “Core data security controls” outlined at http://researchcompliance.umich.edu/data-security-guidelines. Also, consult the Sensitive Data Guide to
IT Services at http://safecomputing.umich.edu/dataguide/ in deciding where to safely store
and share sensitive data using U-M IT services.
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HIPAA PRIVACY RULE COMPLIANCE:
UMHS Privacy Board has not reviewed this project. HIPAA Privacy Rule permits a covered
entity to use and disclose protected health information for quality-related health care
operations activity. Per 45CFR164.502(a)(1):
(1) Permitted uses and disclosures. A covered entity is permitted to use or disclose protected
health information as follows:
(ii) For treatment, payment, or health care operations, as permitted by and in compliance with §
164.506;
The definition at 45CFR164.501 specifies:
Health care operations means any of the following activities of the covered entity to the extent
that the activities are related to covered functions:
(1) Conducting quality assessment and improvement activities, including outcomes evaluation
and development of clinical guidelines, provided that the obtaining of generalizable
knowledge is not the primary purpose of any studies resulting from such activities; …
(2) Reviewing the competence or qualifications of health care professionals, evaluating
practitioner and provider performance, health plan performance, conducting training
programs in which students, trainees, or practitioners in areas of health care learn under
supervision to practice or improve their skills as health care providers, training of nonhealth care professionals, accreditation, certification, licensing, or credentialing activities;
SUBMITTING AMENDMENTS VIA eRESEARCH: You can access the online forms for
amendments in the eResearch workspace for this not regulated project, referenced above.
Note that no Amendment is required by IRBMED except when the design or aims of the
project are changing such that the "Not Regulated" determination may no longer be
appropriate.
ACCESSING NOT REGULATED PROJECTS IN eRESEARCH: Click the "Exempt and Not
Regulated" tab in your eResearch home workspace to access this not regulated project.
Michael Geisser Co-chair, IRBMED
Alan Sugar Co-chair, IRBMED

